Britannia Life Sciences (XCNQ:BLAB) Piotroski F-Score: 7 (As of Sep. 01, 2026) — 40% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Britannia Life Sciences Piotroski F-Score?

Britannia Life Sciences XCNQ:BLAB Piotroski F-Score is 7 as of Sep. 01, 2026, which is 40% above its 10-year median of 5.00. The stock has 5 warning signs investors should review. Among 1,339 Biotechnology companies, Britannia Life Sciences ranks better than 96.94% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Britannia Life Sciences has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Britannia Life Sciences's Piotroski F-Score or its related term are showing as below:

XCNQ:BLAB' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 7
Current: 7

During the past 6 years, the highest Piotroski F-Score of Britannia Life Sciences was 7. The lowest was 3. And the median was 5.

Britannia Life Sciences  (XCNQ:BLAB) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Britannia Life Sciences Piotroski F-Score Related Terms


Britannia Life Sciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Britannia Life Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Britannia Life Sciences Piotroski F-Score Chart

Britannia Life Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial N/A 4.00 3.00 5.00 7.00

Britannia Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 6.00 6.00 6.00 7.00

XCNQ:BLAB vs VRTX, REGN, MRNA: Piotroski F-Score Comparison

For the Biotechnology subindustry, Britannia Life Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Britannia Life Sciences Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Britannia Life Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Britannia Life Sciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -0.691 + -0.411 + 12.128 + 3.625 = C$14.65 Mil.
Cash Flow from Operations was -1.15 + -0.526 + 0.989 + -0.47 = C$-1.16 Mil.
Revenue was 0.17 + 0.211 + 0.377 + -0.283 = C$0.48 Mil.
Gross Profit was 0.028 + 0.138 + 0.348 + -0.412 = C$0.10 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(11.61 + 9.81 + 10.314 + 22.062 + 23.867) / 5 = C$15.5326 Mil.
Total Assets at the begining of this year (Mar25) was C$11.61 Mil.
Long-Term Debt & Capital Lease Obligation was C$0.04 Mil.
Total Current Assets was C$18.79 Mil.
Total Current Liabilities was C$2.86 Mil.
Net Income was -0.738 + -1.195 + -0.137 + 9.462 = C$7.39 Mil.

Revenue was 0.156 + 0.235 + 0.168 + -0.189 = C$0.37 Mil.
Gross Profit was 0.099 + 0.156 + 0.062 + -0.29 = C$0.03 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(22.262 + 21.729 + 22.756 + 22.167 + 11.61) / 5 = C$20.1048 Mil.
Total Assets at the begining of last year (Mar24) was C$22.26 Mil.
Long-Term Debt & Capital Lease Obligation was C$1.66 Mil.
Total Current Assets was C$9.93 Mil.
Total Current Liabilities was C$3.65 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Britannia Life Sciences's current Net Income (TTM) was 14.65. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Britannia Life Sciences's current Cash Flow from Operations (TTM) was -1.16. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=14.651/11.61
=1.26192937

ROA (Last Year)=Net Income/Total Assets (Mar24)
=7.392/22.262
=0.33204564

Britannia Life Sciences's return on assets of this year was 1.26192937. Britannia Life Sciences's return on assets of last year was 0.33204564. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Britannia Life Sciences's current Net Income (TTM) was 14.65. Britannia Life Sciences's current Cash Flow from Operations (TTM) was -1.16. ==> -1.16 <= 14.65 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.035/15.5326
=0.00225333

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1.657/20.1048
=0.08241813

Britannia Life Sciences's gearing of this year was 0.00225333. Britannia Life Sciences's gearing of last year was 0.08241813. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=18.788/2.861
=6.56693464

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=9.925/3.653
=2.71694498

Britannia Life Sciences's current ratio of this year was 6.56693464. Britannia Life Sciences's current ratio of last year was 2.71694498. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Britannia Life Sciences's number of shares in issue this year was 162.254. Britannia Life Sciences's number of shares in issue last year was 162.254. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.102/0.475
=0.21473684

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.027/0.37
=0.07297297

Britannia Life Sciences's gross margin of this year was 0.21473684. Britannia Life Sciences's gross margin of last year was 0.07297297. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=0.475/11.61
=0.04091301

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0.37/22.262
=0.01662025

Britannia Life Sciences's asset turnover of this year was 0.04091301. Britannia Life Sciences's asset turnover of last year was 0.01662025. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Britannia Life Sciences has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Britannia Life Sciences (XCNQ:BLAB) has a Piotroski F-Score of 7 as of Sep. 01, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Britannia Life Sciences and its competitors. This is 40% above median its historical median of 5.00. Over the past decade, Britannia Life Sciences' Piotroski F-Score has ranged from 3.00 to 7.00. According to the industry distribution chart, Britannia Life Sciences ranks #41 out of 1339 companies in the Biotechnology industry, placing it in the top 3.1%.
Is Britannia Life Sciences' Piotroski F-Score too high?
Britannia Life Sciences' current Piotroski F-Score of 7 is 40% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. Britannia Life Sciences' value of 7 is 133.3% above this industry median. Based on the distribution chart, Britannia Life Sciences ranks #41 out of 1339 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Britannia Life Sciences' Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Britannia Life Sciences ranks #41 out of 1339 companies for Piotroski F-Score. This places Britannia Life Sciences in the top 3% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Britannia Life Sciences' value of 7 is 133.3% above this benchmark. Historically, Britannia Life Sciences' own Piotroski F-Score has ranged from 3.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.00, Britannia Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,339 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Britannia Life Sciences's current Piotroski F-Score of 7 is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Britannia Life Sciences and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Britannia Life Sciences's current Piotroski F-Score is 7, which is 40% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Britannia Life Sciences stock overvalued right now?
Britannia Life Sciences (XCNQ:BLAB) has a current Piotroski F-Score of 7. The current Piotroski F-Score is 7, which is 40% above median its 10-year median of 5.00 and 133.3% above the Biotechnology industry median of 3.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Britannia Life Sciences (XCNQ:BLAB), the current Piotroski F-Score is 7 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Britannia Life Sciences Business Description

Address 120 Adelaide Street West, Suite 2400, Toronto, ON, CAN, M5H 1T1
Britannia Life Sciences Inc provides product testing, safety assessment, and manufacturing services to the cosmetic and consumer packaged goods industries in the United Kingdom and globally.